Investigations of the immunopathology of the bronchial wall in asthmatic subjects have shown the presence of a chronic peribronchial inflammation characterised by accumulations of T cells, antigen presenting cells, and macrophages. The increased expression of the CD45RO antigen on the T cells and the increased expression of HLA-DR molecules on the inflammatory cells and the bronchial epithelium that is associated with this T cell dominated inflarLmmation suggest an active acquired cell mediated immune response.5
RFDl and RFD7 to show the relative proportions of RFD1+ RFD7-antigen presenting cells, RFD1-RFD7 + mature phagocytes, and RFDl+ RFD7+ suppressor macrophages. Histological stains were performed to show the presence of eosinophils and mast cells. Three to four weeks after bronchoscopy spirometry was performed on these subjects to record FEV,, forced vital capacity (FVC), FEV,/FVC, and forced expiratory flow between 25% and 75% of vital capacity (FEF2s 5). Bronchial normal volunteers (same criteria as selected orthopaedic patients) underwent three procedures to measure bronchial reactivity (same methods as described above) over one month. This study was conducted to control the design of the original study, in which spirometric and bronchial hyperresponsiveness studies were performed one month after bronchoscopy for logistical reasons.
PREPARATION OF BIOPSY SPECIMENS
The endobronchial biopsies were placed in optimum cutting temperature medium (BDH, Poole) on small cork discs and frozen in isopentane cooled in a bath of liquid nitrogen. The frozen tissues were stored in liquid nitrogen for not more than one month. Sections (6 pm thick) were cut on a cryostat maintained at -25°C and transferred to poly-L-lysine coated slides. These were air dried, fixed in a mixture of chloroform and acetone (1:1), wrapped in cling film, and stored at -20°C until use. At least 40 sections were cut from each biopsy specimen.
HISTOLOGY
Sections from all biopsy specimens were stained with haematoxylin and eosin to show structure and with 0-1% toluidine blue to show mast cells. All these slides were examined by two of us (CP and LWP).
IMMUNOHISTOLOGY
Indirect immunoperoxidase methods were used to reveal specific cell types in the tissues.9 T lymphocytes were identified by using a cocktail of monoclonal antibodies 
Results

SPIROMETRIC RESULTS AND BRONCHIAL REACTIVITY
Spirometric results were normal in the 27 subjects biopsied. The median (range) % predicted FEV, was 100% (67-129%), FVC was 103% (71-129%), and FEF,,-71 was 97% (57-127%). Median bronchial reactivity to histamine was also normal (12-5 mg/ml), although a broad range was seen including nine subjects who recorded a PC2OFEV, of 8 mg/ml or less. The 27 subjects were thus segregated into two groups on the basis of bronchial hyperresponsiveness. Nine patients responded to 8 mg/ml or less of histamine (median (range) PC2,FEV, 5-6 (2-8 mg/ml) and were defined as having bronchial hyperresponsiveness, and the other 18 This increase occurred at the expense of the RFD7 + RFD1-population, whose proportion was significantly reduced.
Discussion
Our study of 27 clinically healthy subjects with no history of any clinically significant lung disease shows that up to 30% of this population were bronchially hyperresponsive as defined by a PC20FEV1 of < 8 mg/ml histamine. As all these subjects regularly participated in sporting activities they may be considered a selected population, and our results do not necessarily indicate the prevalence of bronchial hyperresponsivess in the general population.
Nevertheless, the total absence of any evidence of bronchial inflammation in the subjects showing bronchial hyperresponsiveness suggests that bronchial hyperresponsiveness is not dependent on bronchial inflammation. Furthermore, the presence of bronchial hyperresponsiveness need not in itself cause any inflammatory change in the bronchial wall. Interestingly, even the subject who had abnormal spirometric results (67% predicted FEVI) showed no bronchial hyperreactivity or any evidence of airway inflammation.
Although bronchial hyperresponsiveness has been described as a cardinal feature of asthma,' it is not specific for this disease. '5 Indeed, bronchial hyperresponsiveness defined as an exaggerated response to histamine inhalation may be found in a proportion of the healthy, non-asthmatic population. 2 The accepted cut off point of 8 mg/ml histamine may be too high.'6 Our results support this and suggest that the term bronchial hyperresponsiveness may need to be redefined. It is notable that two of the six subjects used to check reproducibility of results in the lung function laboratory consistently responded to concentrations of histamine lower than 8 mg/ml. Hyperresponsiveness in any given subject might therefore be identified only when a change from baseline values is seen.
Interestingly, the difference in bronchial hyperresponsiveness that segregated the original group of 27 subjects existed in the absence of any difference in spirometric values between the two groups. This observation supports recent data showing that bronchial hyperresponsiveness and spirometry show different kinetics of recovery in patients with acute asthma. ' 
